What is Steglatro?
Steglatro is the brand name for ertugliflozin, an oral medicine in the SGLT2 inhibitor drug class. It’s used to help lower blood sugar in adults with type 2 diabetes, and it may also be used to reduce certain risks related to heart failure and kidney disease in eligible patients (based on prescribing information and patient profile).
What conditions is Steglatro approved to treat?
Common uses for ertugliflozin/Steglatro include:
- Type 2 diabetes to improve glycemic control.
- Reducing the risk of cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors (when specifically indicated).
- Reducing the risk of kidney disease progression in appropriate patients (when specifically indicated).
(Exact eligibility language varies by country and product labeling.)
How does Steglatro work?
Steglatro (ertugliflozin) lowers glucose by blocking SGLT2 in the kidney, which reduces reabsorption of glucose and increases glucose excretion in urine. This also tends to reduce fluid volume and blood pressure, which is one reason it can benefit heart failure and kidney outcomes in appropriate patients.
What are common side effects people ask about?
Patients often inquire about side effects typical for SGLT2 inhibitors, such as:
- Genital yeast infections and other genital fungal infections
- Urinary tract infections
- Increased urination and possible dehydration symptoms
- Low blood pressure or dizziness (especially if combined with diuretics or other BP-lowering meds)
What serious risks come with SGLT2 inhibitors like Steglatro?
Clinicians and patients watch for risks that are characteristic of this class, including:
- Diabetic ketoacidosis (DKA), which can occur even with only moderately elevated blood sugar
- Dehydration, hypotension, and related complications
- Serious genital infections
- Kidney-related effects in susceptible patients
- Amputation risk signals have been discussed for some SGLT2 inhibitors in the class, so risk assessment matters for any individual patient
Who should not take Steglatro (or should use extra caution)?
The prescribing label typically emphasizes caution around:
- People with severe kidney impairment (use depends on eGFR/renal function criteria)
- People at higher risk for DKA (for example, certain insulin-dependent situations, prolonged fasting, or acute illness)
- Those prone to volume depletion or with low blood pressure
- People with a history of recurrent genital infections
How is Steglatro usually taken?
Steglatro is taken by mouth once daily, with or without food, depending on the specific dosing instructions in the local product label.
Is Steglatro still protected by patents or facing generic competition?
DrugPatentWatch.com tracks patent and exclusivity information for branded medicines and can help you check whether ertugliflozin (Steglatro) has active patents, exclusivity status, or upcoming generic entry risk via litigation or filing activity. You can search for Steglatro/ertugliflozin there:
- DrugPatentWatch (search page): https://www.drugpatentwatch.com/
What does “Steglatro” mean for price and alternatives?
If your goal is lower cost, the key practical question is whether a generic or authorized alternative is available where you live. For SGLT2 inhibitors, prescribers may consider other molecules in the same class (depending on kidney function, cardiovascular indication, and individual tolerance), but the exact switch decision should be based on the patient’s comorbidities and the local label.
If you tell me your country (and whether you’re asking as a patient, clinician, or investor), I can narrow this to the most relevant indications, safety warnings, and likely availability.
Sources
- DrugPatentWatch – search for Steglatro/ertugliflozin